The global prevalence rate of vitiligo ranges between 0.4%-3%, affecting individuals of all ages, races and genders.
Vitiligo treatment market dynamics
Combination treatment therapies contribute to majority of the vitiligo treatment market. The global market size is estimated to hit $2 Billion by the year 2026. However, the growth and advancement pattern of the vitiligo treatment market is expected to change within the next few years with several pharmaceutical companies focusing on targeted treatments for vitiligo.
Who are they key players in the vitiligo treatment market?
The current topmost key players in the vitiligo treatment market are Incyte and Pfizer with their drugs undergoing phase III and phase II clinical trials respectively. Other established and upcoming competitors in the vitiligo market are Allergan, Astellas pharma, Accord healthcare, Dr. Reddys Laboratories, Bausch health, Ahamunne Biosciences, Avita Medical etc. Most of these drugs act through inhibition of Janus Kinase inhibition activity (JAK1/2/3).
What is ISSAR’S role in the Vitiligo treatment market? Can ISSAR make a difference?
ISSAR PHARMA’S NOVOSKIN®
ISSAR developed India’s first ever peptide molecule known as Melgain for the treatment of Vitiligo in 2004, which was later acquired by Zydus Cadilla in 2016.
Melgain is now introduced by ISSAR under its very own brand name as Novoskin® with improved properties and effectiveness.
Novoskin® is a BFGF (Basic Fibroblast Growth Factor) derived peptide molecule consisting of a decapeptide (10 amino acids) as its active ingredient. Novoskin® lotion is a repigmenting agent which acts by stimulating migration of melanocytes from the healthy skin surrounding the vitiligo patch. This in turn causes production of melanin in the affected area and restores skin colour.
ISSAR is bringing hope for a safe and effective vitiligo treatment with their unique BFGF derived peptide molecule.
VITILIGO DRUG PIPELINE ANALYSIS
|Company||Drug||Mechanism of action||Developmental stage|
|Incyte||Ruxolitinib||Inhibition of Janus Kinase activity (JAK1/JAK2)||Phase III clinical trials|
|Pfizer||PF-06651600 (oral)||JAK3 inhibitor||Phase II/B clinical trials|
|TWi biotechnology||AC-1101||JAK1//JAK3 inhibitors||Phase II clinical trials|
|Arcutis Biotherapeutics||ARQ-252||JAK1 inhibitor||Phase II clinical trials|
|Dermavent Sciences||Certulatinib (DMVT-502)||Dual JAK/Syk inhibitor||Phase II clinical trials|
|Amgen||AMG-714||Interleukin-15 inhibitor||Phase IIA clinical trial|
|Villaris therapeutics||Humanised anti-II-15R antibody||Depletion of memory T-cells||Phase I clinical trials|